ARS Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

ARS Pharmaceuticals şirketinin kazançları yıllık ortalama -38.3% oranında azalırken, Biotechs sektörünün kazançları yıllık 19.1% oranında artan oldu. Gelirler yıllık ortalama 82.7% oranında azalan oldu.

Anahtar bilgiler

-38.3%

Kazanç büyüme oranı

-4.4%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	-82.7%
Özkaynak getirisi	-24.4%
Net Marj	-1,912.1%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

ARS Pharmaceuticals: Demand Curve Is Key Unknown

Nov 20

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

Sep 13

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

Nov 14

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

May 12

Gelir ve Gider Dağılımı

ARS Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGM:SPRY Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	3	-49	43
30 Jun 24	1	-45	39
31 Mar 24	0	-50	43
31 Dec 23	0	-54	47
30 Sep 23	0	-62	51
30 Jun 23	0	-53	39
31 Mar 23	1	-42	29
31 Dec 22	1	-35	19
30 Sep 22	2	-25	10
30 Jun 22	2	-25	8
31 Mar 22	4	-23	6
31 Dec 21	6	-20	5
31 Dec 20	18	-1	4

Kaliteli Kazançlar: SPRY şu anda kârlı değil.

Büyüyen Kar Marjı: SPRY şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SPRY kârlı değildir ve zararlar son 5 yılda yılda 38.3% oranında artmıştır.

Büyüme Hızlandırma: SPRY 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: SPRY kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 16.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: SPRY hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -24.43% ) sahiptir.

ARS Pharmaceuticals Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2024 earnings released: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.24 loss in 1Q 2022)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Recent updates

ARS Pharmaceuticals: Demand Curve Is Key Unknown

We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow

ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval

ARS Pharmaceuticals, Inc. Launches Pre-Ordering Services for neffy to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals, Inc. Announces Approval of EURneffy (adrenaline nasal spray) in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

ARS Pharmaceuticals, Inc. Receives FDA Approval of Neffy® (Epinephrine Nasal Spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell Small Cap Comp Value Index

ARS Pharmaceuticals, Inc. Announces EURneffy (Adrenaline Nasal Spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (Anaphylaxis)

ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles

First quarter 2024 earnings released: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)

ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

ARS Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Founder exercised options to buy US$1.6m worth of stock.

ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)

Consensus revenue estimates decrease by 19%, EPS upgraded

Full year 2023 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate

ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study

New minor risk - Profitability

Consensus revenue estimates decrease by 25%

Forecast to breakeven in 2026

ARS Pharmaceuticals, Inc. Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

Consensus EPS estimates upgraded to US$0.64 loss

ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.25 loss in 3Q 2022)

Chief Legal Officer & Secretary recently bought US$320k worth of stock

Consensus revenue estimates decrease by 99%, EPS upgraded

ARS Pharmaceuticals, Inc. Announces FDA Issues Complete Response Letter for neffy(R) (epinephrine nasal spray) New Drug Application with Request for Additional Study

Co-Founder & Chief Science Officer recently sold US$26m worth of stock

Second quarter 2023 earnings released: US$0.18 loss per share (vs US$0.21 loss in 2Q 2022)

Consensus revenue estimates fall by 67%

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.24 loss in 1Q 2022)

Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings released

ARS Pharmaceuticals, Inc. Appoints Brian T. Dorsey as Chief Operations Officer

Chief Financial Officer recently bought US$52k worth of stock

No independent directors

ARS Pharmaceuticals, Inc. Announces Presentation of Clinical Data Supporting Neffy® for the Treatment of Allergic Reactions (Type I) Including Anaphylaxis

ARS Pharmaceuticals, Inc. Announces Board Changes

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin